CSL (OTCMKTS:CSLLY) Stock Rating Lowered by Citigroup

CSL (OTCMKTS:CSLLY) was downgraded by equities research analysts at Citigroup from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Royal Bank Of Canada cut shares of CSL from a “moderate buy” rating to a “hold” rating in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CSL has an average rating of “Hold”.

CSL Stock Down 1.9%

CSL stock opened at $17.75 on Monday. The company’s fifty day simple moving average is $24.02 and its 200-day simple moving average is $46.65. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57. CSL has a 12 month low of $17.64 and a 12 month high of $44.86.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.